On the other hand, introduction of a DN-TP53 gene into LNCaP and 22RV-1 prostate cancer cells, which contain WT TP53, resulted in decreased sensitivity to chemotherapeutic drugs and ionizing radiation [4, 5]. Here, TP53 is linked to prostate carcinoma.